|
|
|
|
|
|
|
21.08.25 - 18:06
|
BriaCell Announces Proposed Effective Date of Share Consolidation (GlobeNewswire EN)
|
|
|
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company's board of directors has approved the consolidation (the “Consolidation”) of the Company's issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”)....
|
|
|
|
|
|
|
21.08.25 - 14:18
|
Bausch Health Companies Inc.: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, CABTREO, Now Available Through Public Drug Plans of Quebec and Saskatchewan (Accesswire)
|
|
|
LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced t......
|
|
|
|
|
21.08.25 - 13:03
|
Quantum BioPharma Announces Corporate Updates (GlobeNewswire EN)
|
|
|
TORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate updates:...
|
|
|
|
|
|
|
21.08.25 - 11:15
|
Thiogenesis-Aktie: +1.000% Fantasie? (Sharedeals)
|
|
|
Während die Quartalszahlen kaum Beachtung fanden, schlummert in der Pipeline dieses Unternehmens explosives Potenzial. Ein einziger Wirkstoff wird für drei verschiedene Krankheiten getestet, was das Risiko für Anleger streut. Mit einer Marktkapitalisierung von unter 40 Millionen CAD scheint die Aktie für risikobewusste Anleger eine hochinteressante Wette zu sein. Anfang der Woche hat Thiogenesis seine Zahlen […]
The post Thiogenesis-Aktie: +1.000% Fantasie? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
